Legislation & Advocacy

HB 2871 was signed into law.

• October 2025: Arizona researchers can now apply for $5 million to study Ibogaine! The state has released a $5 million RFP to fund phase I clinical trials, signaling a major investment in early-stage medical research.
• June 2025: HB 2871 signed into law. Appropriates $5,000,000.
• March 2025: HB 2871 passed out of the Senate Committee on Health Services by a vote of 10-0.
• February 2025: House Bill 2871 is introduced by Rep. Wilmeth (R)

AB 1103 was signed into law.

• October 2025: Gov. Newsom signs AB 1103 into law, which streamlines California’s approval process for federally authorized clinical research involving Schedule I and II substances such as psilocybin, MDMA, and ibogaine, by allowing expedited review through a subcommittee of the state’s Research Advisory Panel.

HB 1001 was signed into law.

• July 2025: Indiana joins the growing list of states exploring ibogaine research through new bipartisan legislation. HB 1001 was signed by the Speaker of the House on April 25 and enacted as Public Law 213, taking effect on July 1. The law expands the state’s therapeutic psilocybin research fund to include research on ibogaine.

SB 2308 was signed into law.

• December 2025: UTHealth Houston, in collaboration with UTMB Health, was awarded $50 million by the state of Texas to lead ibogaine clinical trials.
• June 2025: Gov. Greg Abbott (R) signed Senate Bill 2308 into law. SB2308 allocates funding for clinical trials exploring the pharmaceutical applications of ibogaine. The measure authorizes $50 million in grants for organizations capable of conducting FDA-supervised studies — the largest state investment in ibogaine research in U.S. history.
• March 2025: House Bill 3717 is introduced by Rep. Cody Harris (R), which would fund FDA-approved clinical trials of ibogaine—a potential breakthrough treatment for opioid use disorder, co-occurring substance use disorders, and other mental health conditions.

HB 26-1325 has been introduced.

• March 2026: HB26-1325 establishes the ibogaine research pilot program (pilot program) in the behavioral health administration (BHA) to research the safety and effectiveness of using ibogaine to treat mental health conditions and substance use disorders.

SB 77 has been introduced.

• March 2026: SB 77 passed out of the Senate Committee on Health Services by a vote of 10-0.
• January 2026: Senate Bill 77 is introduced by Sen. Donald Douglas (R). If passed, it will appropriate $21,000,000 each fiscal year of the 2026-2028 fiscal biennium to create a framework to study the use of ibogaine to treat substance use disorders.

SB 43 has been introduced.

• February 2026: Senate Bill 43 is introduced by Sen. Patrick McMath (R) and would establish a program within the Louisiana Department of Health to facilitate clinical studies on psychedelic-assisted therapy, which involves administering psychedelic medications like psilocybin or ibogaine in a controlled setting alongside psychotherapy.

SB 527 / HB 1477 have been introduced.

• March 2026: HB 1477 heard in the House Committee on Health.
• February 2026: SB 527 heard in the Senate Committee on Finance.
• February 2026: Senate Bill 527 is introduced by Sen. Kevin M. Harris (D) & House Bill 1477 is introduced by several Representatives (D). Appropriates $500,000 each fiscal year from 2028 through 2030.

HB 314 has been introduced.

• March 2026: HB 314 was passed by the Mississippi Senate by a vote of 51-1.
• January 2026: HB 314 passed the Mississippi House of Representatives by a vote of 110-1.
• January 2026: HB 314 heard in the House Committee on Public Health & Human Services.
• January 2026: House Bill 314 is introduced by Rep. Sam Creekmore IV (R), Chairman of the House Public Health and Human Services Committee. Appropriates $5,000,000 and aims to form a consortium, a collaborative partnership between researchers and institutions, with the eventual goal of getting ibogaine approved by the U.S. Food and Drug Administration as a medication.

HB 2961 has been introduced.

• February 2026: HB 2961 passed out of the House Committee on Emerging Issues by a vote of 8-1-2.
• February 2026: HB 2961 referred to the House Committee on Emerging Issues.
• January 2026: House Bill 2961 is introduced by Rep. Richard West (R). This bill, known as the “Veterans Mental Health Innovation Act,” establishes provisions for the research and potential treatment use of ibogaine, a substance and ibogaine-based therapeutics, for conditions like opioid use disorder and other neurological or mental health issues.

HB 1772 has been introduced.

• February 2026: HB 1772 passes out of the House Committee on Health, Human Services & Elderly Affairs by a vote of 10-8.
• February 2026: House Bill 1772 was introduced by Rep. Michael Moffett (R). HB1772 recommends participation in a multistate consortium to conduct clinical trials using ibogaine as an investigational new drug for the treatment of substance use disorder and other neurological or mental health conditions, and making an appropriation therefor.

AB 9583 has been introduced.

• January 2026: Assembly Bill 9583 is introduced by Assemblymember Robert Smullen (R). AB9583 would establish a research grant program to fund clinical trials of ibogaine for the treatment of veterans with post-traumatic stress disorder; it creates a fund to provide monies for the research grant program.

HB 3834 has been introduced.

• March 2026: HB 3834 passed out of the Oklahoma House of Representatives by a vote of 68-23.
• February 2026: House Bill 3834 is introduced by Rep. Stan May (R). The Oklahoma Breakthrough Therapy Act establishes a framework for conducting clinical trials of ibogaine, a substance being investigated for therapeutic uses, by defining “drug developer” as an entity engaged in drug development with an agreement to conduct trials for United States Food and Drug Administration (FDA) approval.

HB 4110 has been introduced.

• February 2026: HB 4110 heard in the House Committee on Behavioral Health.
• February 2026: House Bill 4110 is introduced by Rep. Alek Skarlatos (R), which would allow an attending physician to provide ibogaine to a patient for the patient’s consumption to treat certain disorders.

SB 2149 and HB 2075 have been introduced.

• March 2026: HB 2075 heard in the House Health Committee.
• March 2026: SB 2149 heard in the Senate Committee on Health & Welfare.
• February 2026: Senate Bill 2149 is introduced by Sen. Page Walley (R), and House Bill 2075 is introduced by Rep. Bryan Terry. Enacts the “Helping Open Pathways to Effective (HOPE) Treatment Act,” which establishes a framework for conducting clinical trials in Tennessee for ibogaine, a substance being investigated for treating opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions.

HB 4626 has been introduced.

• February 2026: HB 859 referred to the House Committee on Health Care.
• February 2026: House Bill 859 is introduced by Rep. Brian Cina (D), which seeks to divert state funds from the Opioid Abatement Special Fund.

HB 4626 has been introduced.

• March 2026: HB 4626 passed out of the West Virginia Senate by a vote of 34-0.
• January 2026: HB 4626 passed out of the Virginia House of Representatives by a vote of 96-0.
• January 2026: House Bill 4626 is introduced by Delegate Ryan Browning (R) relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine.

Study Committee created to examine ibogaine and related therapies.

• January 2026: Rep. Justin Pizzulli (R) has been named Chairman of The Ibogaine Treatment Study Committee, which held its first meeting of the 2026 legislative session.
• December 2025: The State Operating Budget for fiscal years 2026-27 included a provision to establish the Ibogaine Treatment Study Committee, which is tasked with evaluating and providing recommendations on the use of ibogaine for treating individuals with substance use disorders and veterans with post-traumatic stress disorder, depression, and mild traumatic brain injuries.